Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTOR | P42345 | 18/20 | 0.53 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.53 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.53 |
| ▸ | ATR | Q13535 | 3/20 | 0.43 |
| ▸ | CHEK1 | O14757 | 2/20 | 0.43 |
| ▸ | ATM | Q13315 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1609664 | 1.00 | MTOR (0.53) | MTORPIK3CDPIK3CAATRCHEK1 | |
| SCHEMBL1608742 | 1.00 | MTOR (0.53) | MTORPIK3CDPIK3CAATRCHEK1 | |
| SCHEMBL1608473 | 0.86 | MTOR (0.56) | MTORPIK3CDPIK3CAATR | |
| SCHEMBL1608475 | 0.86 | MTOR (0.56) | MTORPIK3CDPIK3CAATR | |
| SCHEMBL1608931 | 0.85 | MTOR (0.57) | MTORPIK3CDPIK3CAATRCHEK1 | |
| SCHEMBL1608927 | 0.85 | MTOR (0.57) | MTORPIK3CDPIK3CAATRCHEK1 | |
| SCHEMBL1611445 | 0.81 | MTOR (0.53) | MTORPIK3CDPIK3CAATRCHEK1 | |
| SCHEMBL1611443 | 0.81 | MTOR (0.53) | MTORPIK3CDPIK3CAATRCHEK1 | |
| SCHEMBL2673181 | 0.81 | MTOR (0.53) | MTORPIK3CDPIK3CAATRCHEK1 | |
| SCHEMBL31339147 | 0.79 | MTOR (0.48) | MTORPIK3CDPIK3CACHEK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2499143-B1 | N7-SUBSTITUTED PURINE AND PYRAZOLOPYRIMIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE | HOFFMANN LA ROCHE (CH) | 2016-03-16 | — | — | EP | disclosed |
| US-8828990-B2 | N-7 substituted purine and pyrazolopyrimine compounds, compositions and methods of use | GENENTECH, INC. (US) | 2014-09-09 | — | — | US | disclosed |
| EP-2499143-A1 | N-7 SUBSTITUTED PURINE AND PYRAZOLOPYRIMIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE | F. Hoffmann-La Roche AG (CH) | 2012-09-19 | — | — | EP | disclosed |
| WO-2011058025-A1 | N-7 SUBSTITUTED PURINE AND PYRAZOLOPYRIMIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE | F. HOFFMANN-LA ROCHE AG (CH) | 2011-05-19 | — | — | WO | disclosed |
| US-20110086840-A1 | N-7 SUBSTITUTED PURINE AND PYRAZOLOPYRIMINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE | GENENTECH, INC. (US) | 2011-04-14 | — | — | US | disclosed |
| US-20110086840-A1 | N-7 SUBSTITUTED PURINE AND PYRAZOLOPYRIMINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE | GENENTECH, INC. (US) | 2011-04-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110086840-A1 | N-7 SUBSTITUTED PURINE AND PYRAZOLOPYRIMINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE | P2RX7, P2RY1, PNP | MTOR 3024/4885PIK3CD 2269/4885PIK3CA 889/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.